{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:23:09Z","timestamp":1789129389557,"version":"build-2803163510"},"reference-count":167,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01NS128336"],"award-info":[{"award-number":["1R01NS128336"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01NS116037"],"award-info":[{"award-number":["1R01NS116037"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006458","name":"Children's Hospital of Philadelphia","doi-asserted-by":"publisher","award":["LB805"],"award-info":[{"award-number":["LB805"]}],"id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["1R01NS128336"],"award-info":[{"award-number":["1R01NS128336"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbcan.2025.189480","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T06:45:41Z","timestamp":1761288341000},"page":"189480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nanoparticulate delivery and targeting of RNA to the brain"],"prefix":"10.1016","volume":"1880","author":[{"given":"Aditya","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chittalsinh M.","family":"Raulji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"I. Mahato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2025.189480_bb0005","series-title":"Neuroimmune Pharmacology and Therapeutics","first-page":"585","article-title":"Pharmacogenomics of neurodegenerative diseases: roles in personalized medicines","author":"Gupta","year":"2024"},{"key":"10.1016\/j.bbcan.2025.189480_bb0010","author":"b. tumor"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189480_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrd.2018.14","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189480_bb0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/molecules27020536","article-title":"Small drugs, huge impact: the extraordinary impact of antisense oligonucleotides in research and drug development","volume":"27","author":"Quemener","year":"2022","journal-title":"Molecules"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189480_bb0025","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189480_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","article-title":"Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications","volume":"266","author":"Liu","year":"2017","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189480_bb0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189480_bb0040","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","article-title":"Viral vectors for gene therapy: translational and clinical outlook","volume":"17","author":"Kotterman","year":"2015","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189480_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1853","article-title":"Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications","volume":"15","author":"Yang","year":"2023","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189480_bb0055","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189480_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202100109","article-title":"Lipid nanoparticles for drug delivery","volume":"2","author":"Xu","year":"2022","journal-title":"Adv. NanoBiomed Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189480_bb0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2025.189480_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114115","article-title":"Nanomedicine for brain cancer","volume":"182","author":"Quader","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2025.189480_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-2289-6_1","article-title":"Cells of the blood-brain barrier: an overview of the neurovascular unit in health and disease","volume":"2492","author":"McConnell","year":"2022","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."},{"issue":"46","key":"10.1016\/j.bbcan.2025.189480_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201801362","article-title":"Overcoming the blood\u2013brain barrier: the role of nanomaterials in treating neurological diseases","volume":"30","author":"Furtado","year":"2018","journal-title":"Adv. Mater."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189480_bb0090","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/d41573-021-00164-x","article-title":"Gene therapy community grapples with toxicity issues, as pipeline matures","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2025.189480_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cobme.2017.09.002","article-title":"Nanomaterials for convection-enhanced delivery of agents to treat brain tumors","volume":"4","author":"Seo","year":"2017","journal-title":"Curr. Opin. Biomed. Eng."},{"issue":"41","key":"10.1016\/j.bbcan.2025.189480_bb0100","doi-asserted-by":"crossref","first-page":"E9590","DOI":"10.1073\/pnas.1719642115","article-title":"Mechanism of drug extrusion by brain endothelial cells via lysosomal drug trapping and disposal by neutrophils","volume":"115","author":"Noack","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189480_bb0105","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jconrel.2015.09.046","article-title":"Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles","volume":"219","author":"Bishop","year":"2015","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0110","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.4103\/1673-5374.335830","article-title":"Brain delivering RNA-based therapeutic strategies by targeting mTOR pathway for axon regeneration after central nervous system injury","volume":"17","author":"Li","year":"2022","journal-title":"Neural Regen. Res."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189480_bb0115","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0120","article-title":"Broadening the horizons of RNA delivery strategies in cancer therapy","volume":"9","author":"Wu","year":"2022","journal-title":"Bioengineering (Basel)"},{"issue":"23","key":"10.1016\/j.bbcan.2025.189480_bb0125","doi-asserted-by":"crossref","first-page":"20234","DOI":"10.1021\/acsomega.3c01703","article-title":"Emergence of Small interfering RNA-based gene drugs for various diseases","volume":"8","author":"Kurakula","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbcan.2025.189480_bb0130","article-title":"Not making the cut: techniques to prevent RNA cleavage in structural studies of RNase-RNA complexes","volume":"6","author":"Jones","year":"2022","journal-title":"J. Struct. Biol. X"},{"key":"10.1016\/j.bbcan.2025.189480_bb0135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2015.12.041","article-title":"Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system","volume":"240","author":"Crawford","year":"2016","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189480_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073742","article-title":"Disease-induced modulation of drug transporters at the blood-brain barrier level","volume":"22","author":"Al Rihani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11095-022-03433-5","article-title":"CNS delivery of nucleic acid therapeutics: beyond the blood-brain barrier and towards specific cellular targeting","volume":"40","author":"D\u2019Souza","year":"2023","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189480_bb0155","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics - challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189480_bb0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cts.12624","article-title":"Targeting RNA: a transformative therapeutic strategy","volume":"12","author":"Yin","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bbcan.2025.189480_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010746","article-title":"Clinical pharmacokinetics of approved RNA therapeutics","volume":"24","author":"Jo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.bbcan.2025.189480_bb0175","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114760","article-title":"RNA-based medicine: from molecular mechanisms to therapy","volume":"42","author":"Sparmann","year":"2023","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189480_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9050512","article-title":"Chemical manipulation of the endosome trafficking machinery: implications for oligonucleotide delivery","volume":"9","author":"Juliano","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0185","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: how do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189480_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA therapeutics: the great endosomal escape!","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid Ther."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189480_bb0195","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.2174\/0113892010291042240130171709","article-title":"RNA-based therapeutics: past, present and future prospects, challenges in cancer treatment","volume":"25","author":"Goel","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bbcan.2025.189480_bb0200","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.addr.2020.04.002","article-title":"Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes","volume":"159","author":"Veiga","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0205","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s12672-025-03070-5","article-title":"mRNA vaccines and SiRNAs targeting cancer immunotherapy: challenges and opportunities","volume":"16","author":"Lv","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189480_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood-brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"van Tellingen","year":"2015","journal-title":"Drug Resist. Updat."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0225","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1158\/1078-0432.CCR-14-0084","article-title":"ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy","volume":"20","author":"Lin","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0230","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the road for RNA therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189480_bb0235","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/d41573-023-00103-y","article-title":"FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189480_bb0240","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/d41573-022-00001-9","article-title":"2021 FDA approvals","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0245","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cells13100800","article-title":"CRISPR-based gene therapies: from preclinical to clinical treatments","volume":"13","author":"Laurent","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189480_bb0250","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ph18030291","article-title":"2024 FDA TIDES (peptides and oligonucleotides) harvest","volume":"18","author":"Al Musaimi","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189480_bb0260","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.xphs.2024.04.021","article-title":"A review on commercial oligonucleotide drug products","volume":"113","author":"Vinjamuri","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbcan.2025.189480_bb0265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jconrel.2019.11.009","article-title":"Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes","volume":"317","author":"Kim","year":"2020","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189480_bb0270","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ymthe.2025.02.045","article-title":"Clinical applications of oligonucleotides for cancer therapy","volume":"33","author":"DeFranciscis","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2025.189480_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1414658","article-title":"Antisense oligonucleotides and their applications in rare neurological diseases","volume":"18","author":"McDowall","year":"2024","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0280","first-page":"194","article-title":"Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J. Pediatr. Pharmacol. Ther."},{"issue":"21","key":"10.1016\/j.bbcan.2025.189480_bb0285","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1002\/anie.201914751","article-title":"Systemic brain delivery of antisense oligonucleotides across the blood-brain barrier with a glucose-coated polymeric nanocarrier","volume":"59","author":"Min","year":"2020","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.bbcan.2025.189480_bb0290","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2018.05.010","article-title":"Angubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system","volume":"283","author":"Zeniya","year":"2018","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0295","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","article-title":"RNA interference in the era of nucleic acid therapeutics","volume":"42","author":"Jadhav","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2025.189480_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2021.694838","article-title":"RNA interference and nanotechnology: a promising alliance for next generation cancer therapeutics","volume":"3","author":"Swaminathan","year":"2021","journal-title":"Front. Nanotechnol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189480_bb0305","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbcan.2025.189480_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0315","doi-asserted-by":"crossref","first-page":"416","DOI":"10.26599\/NBE.2024.9290086","article-title":"Preparation of Bmi-1-siRNA lipid nanoparticles and effects in gastric cancer","volume":"16","author":"Yan","year":"2024","journal-title":"Nano Biomed. Eng."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0320","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1021\/mp9000469","article-title":"TGF-\u03b21 gene silencing for treating liver fibrosis","volume":"6","author":"Cheng","year":"2009","journal-title":"Mol. Pharm."},{"issue":"5689","key":"10.1016\/j.bbcan.2025.189480_bb0325","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.1102513","article-title":"Argonaute2 is the catalytic engine of mammalian RNAi","volume":"305","author":"Liu","year":"2004","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189480_bb0330","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","article-title":"Interfering with disease: a progress report on siRNA-based therapeutics","volume":"6","author":"de Fougerolles","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189480_bb0335","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1007\/s11095-011-0608-1","article-title":"Subcellular fate and off-target effects of siRNA, shRNA, and miRNA","volume":"28","author":"Singh","year":"2011","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189480_bb0340","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.3390\/cancers13112680","article-title":"MicroRNA therapeutics in cancer: current advances and challenges","volume":"13","author":"Reda El Sayed","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2025.189480_bb0345","series-title":"MicroRNA Databases, miRNAs, Human Health and Diseases","first-page":"21","author":"Hansel Fr\u00f6se","year":"2024"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0350","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.047662","article-title":"Tran, miRNA interplay: mechanisms and consequences in cancer","volume":"14","author":"Hill","year":"2021","journal-title":"Dis. Model. Mech."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0355","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189480_bb0360","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189480_bb0365","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","article-title":"Therapeutic induction of antigen-specific immune tolerance","volume":"24","author":"Kenison","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2025.189480_bb0370","article-title":"mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0375","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.bbcan.2025.189480_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101790","article-title":"Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma","volume":"49","author":"Liu","year":"2023","journal-title":"Nano Today"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0385","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189480_bb0390","first-page":"353","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing","author":"Asmamaw","year":"2021","journal-title":"Biologics Targets Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0395","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41578-024-00725-7","article-title":"CRISPR\u2013Cas9 delivery strategies for the modulation of immune and non-immune cells","volume":"10","author":"Alsaiari","year":"2025","journal-title":"Nat. Rev. Mater."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0400","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3","volume":"118","author":"Qiu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189480_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189480_bb0410","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1093\/nar\/gkv226","article-title":"Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference","volume":"43","author":"Barrangou","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189480_bb0415","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/crispr.2020.0134","article-title":"Dead Cas9\u2013sgRNA complex shelters vulnerable DNA restriction enzyme sites from cleavage for cloning applications","volume":"4","author":"Saifaldeen","year":"2021","journal-title":"CRISPR J."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189480_bb0420","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0425","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide\u2013protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189480_bb0430","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189480_bb0435","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2025.189480_bb0440","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.omtn.2022.05.024","article-title":"RNA modifications can affect RNase H1-mediated PS-ASO activity","volume":"28","author":"Doxtader Lacy","year":"2022","journal-title":"Mol. Ther. Nucleic Acids."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189480_bb0445","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/nar\/gkf412","article-title":"Antisense properties of tricyclo-DNA","volume":"30","author":"Renneberg","year":"2002","journal-title":"Nucleic Acids Res."},{"issue":"89","key":"10.1016\/j.bbcan.2025.189480_bb0450","doi-asserted-by":"crossref","first-page":"13024","DOI":"10.1039\/D4CC04302B","article-title":"Conformation matters: siRNAs with antisense strands with 5\u2032-(E)-vinyl-phosphonate-\u03b1-l-LNA elicit stronger RNAi-mediated gene silencing than those with 5\u2032-(E)-vinyl-phosphonate-LNA","volume":"60","author":"Datta","year":"2024","journal-title":"Chem. Commun."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189480_bb0455","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1093\/nar\/gkx507","article-title":"5\u0384-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo","volume":"45","author":"Haraszti","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0460","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1021\/acs.jmedchem.7b01147","article-title":"Facile synthesis, geometry, and 2\u2019-substituent-dependent in vivo activity of 5\u2032-(E)- and 5\u2032-(Z)-Vinylphosphonate-modified siRNA conjugates","volume":"61","author":"Parmar","year":"2018","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102312","article-title":"Stereopure ASOs: An unanticipated increase in selectivity for targeting mutant HTT","volume":"35","author":"Gulumkar","year":"2024","journal-title":"Mol. Ther. Nucleic Acids."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102246","article-title":"Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT","volume":"35","author":"Iwamoto","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0475","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1021\/acs.molpharmaceut.0c01238","article-title":"Advances in the design of (Nano)formulations for delivery of antisense oligonucleotides and Small interfering RNA: focus on the central nervous system","volume":"18","author":"Mendon\u00e7a","year":"2021","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189480_bb0480","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189480_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020760","article-title":"Nanocarriers for delivery of oligonucleotides to the CNS","volume":"23","author":"Male","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0490","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"Pt A","key":"10.1016\/j.bbcan.2025.189480_bb0495","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2025.189480_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120272","article-title":"Exploring the therapeutic potential of the bioinspired reconstituted high density lipoprotein nanostructures","volume":"596","author":"Gupta","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0505","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bbcan.2025.189480_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113902","article-title":"COG133 peptide-conjugated lipid nanoparticles sensitize medulloblastoma to radiation therapy in mice","volume":"384","author":"Gupta","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189480_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114266","article-title":"Lipid nanomedicine simultaneously inhibits BRD4\/PI3K and MDM2\/XIAP signaling pathways for effective treatment of medulloblastoma","volume":"387","author":"Sethi","year":"2025","journal-title":"J. Control. Release"},{"issue":"30","key":"10.1016\/j.bbcan.2025.189480_bb0520","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb4429","article-title":"Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection","volume":"6","author":"Ma","year":"2025","journal-title":"Sci. Adv."},{"issue":"47","key":"10.1016\/j.bbcan.2025.189480_bb0525","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0530","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Protoc."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0535","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0540","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/bc300381s","article-title":"The headgroup evolution of cationic lipids for gene delivery","volume":"24","author":"Zhi","year":"2013","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0545","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103505","article-title":"Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids","volume":"28","author":"Mendon\u00e7a","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189480_bb0555","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2014.84","article-title":"In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight","volume":"9","author":"Dahlman","year":"2014","journal-title":"Nat. Nanotechnol."},{"issue":"45","key":"10.1016\/j.bbcan.2025.189480_bb0560","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189480_bb0565","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1021\/ar500260t","article-title":"The structural role of cholesterol in cell membranes: from condensed bilayers to lipid rafts","volume":"47","author":"Krause","year":"2014","journal-title":"Acc. Chem. Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189480_bb0570","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1021\/acs.nanolett.0c01386","article-title":"Deconvoluting lipid nanoparticle structure for messenger RNA delivery","volume":"20","author":"Eygeris","year":"2020","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0575","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189480_bb0580","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.bbcan.2025.189480_bb0585","doi-asserted-by":"crossref","DOI":"10.1021\/bc400055h","article-title":"B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide","volume":"24","author":"Liu","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bbcan.2025.189480_bb0590","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1016\/j.biomaterials.2009.02.051","article-title":"Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles","volume":"30","author":"Liu","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbcan.2025.189480_bb0595","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2005.07.013","article-title":"Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier","volume":"108","author":"Costantino","year":"2005","journal-title":"J. Control. Release."},{"key":"10.1016\/j.bbcan.2025.189480_bb0600","article-title":"Novel peptide-conjugated nanomedicines for brain targeting: in vivo evidence, nanomedicine: nanotechnology","volume":"28","author":"Duskey","year":"2020","journal-title":"Biol. Med."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189480_bb0605","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1523\/JNEUROSCI.1980-20.2020","article-title":"Zinc status alters Alzheimer\u2019s disease progression through NLRP3-dependent inflammation","volume":"41","author":"Rivers-Auty","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbcan.2025.189480_bb0610","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejps.2018.01.028","article-title":"Lamotrigine loaded poly-\u025b-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system","volume":"115","author":"Ammar","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2025.189480_bb0615","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijpharm.2018.10.022","article-title":"Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma","volume":"553","author":"Di Mauro","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189480_bb0620","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8011","article-title":"Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy","volume":"8","author":"Zou","year":"2022","journal-title":"Sci. Adv."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189480_bb0625","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25163731","article-title":"Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology","volume":"25","author":"Zieli\u0144ska","year":"2020","journal-title":"Molecules"},{"issue":"10200","key":"10.1016\/j.bbcan.2025.189480_bb0630","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0635","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1021\/acs.bioconjchem.9b00306","article-title":"Antibody\u2013oligonucleotide conjugates as therapeutic, imaging, and detection agents","volume":"30","author":"Dovgan","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189480_bb0640","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/molecules26195847","article-title":"An insight into FDA approved antibody-drug conjugates for cancer therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189480_bb0645","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189480_bb0650","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody\u2013oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189480_bb0655","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/nar\/gku1362","article-title":"Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates","volume":"43","author":"Cuellar","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189480_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189480_bb0665","unstructured":"Avidity Biosciences 2025."},{"key":"10.1016\/j.bbcan.2025.189480_bb0670","unstructured":"D. Therapeutics 2025."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189480_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/cells12192395","article-title":"Enhancing antisense oligonucleotide-based therapeutic delivery with DG9, a versatile cell-penetrating peptide","volume":"12","author":"Haque","year":"2023","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189480_bb0680","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1172\/JCI128205","article-title":"Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice","volume":"129","author":"Klein","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0685","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/npp.2011.196","article-title":"Transferrin antibodies into the brain","volume":"37","author":"Dennis","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuron.2013.12.023","article-title":"Breaching the blood-brain barrier for drug delivery","volume":"81","author":"Bell","year":"2014","journal-title":"Neuron"},{"issue":"84","key":"10.1016\/j.bbcan.2025.189480_bb0695","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0700","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.bbcan.2025.189480_bb0705","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jare.2023.01.005","article-title":"Antisense-oligonucleotide co-micelles with tumor targeting peptides elicit therapeutic effects by inhibiting microRNA-21 in the glioblastoma animal models","volume":"53","author":"Lee","year":"2023","journal-title":"J. Adv. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0710","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40263-020-00781-x","article-title":"Intranasal insulin for Alzheimer\u2019s disease","volume":"35","author":"Hallschmid","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbcan.2025.189480_bb0715","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.actbio.2022.11.013","article-title":"A simple self-assembly nanomicelle based on brain tumor-targeting peptide-mediated siRNA delivery for glioma immunotherapy via intranasal administration","volume":"155","author":"Tang","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbcan.2025.189480_bb0720","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2021.01.027","article-title":"Minimally invasive nasal depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain","volume":"331","author":"Padmakumar","year":"2021","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061694","article-title":"Permeabilization of the blood-brain barrier via mucosal engrafting: implications for drug delivery to the brain","volume":"8","author":"Bleier","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189480_bb0730","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.7150\/thno.65539","article-title":"Claudin-5 binder enhances focused ultrasound-mediated opening in an in vitro blood-brain barrier model","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"18","key":"10.1016\/j.bbcan.2025.189480_bb0735","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf7390","article-title":"Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles","volume":"7","author":"Guo","year":"2021","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189480_bb0740","doi-asserted-by":"crossref","first-page":"N65","DOI":"10.1088\/0031-9155\/57\/7\/N65","article-title":"Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood-brain barrier using focused ultrasound and microbubbles","volume":"57","author":"Baseri","year":"2012","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.bbcan.2025.189480_bb0745","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jconrel.2021.12.005","article-title":"Liposome delivery to the brain with rapid short-pulses of focused ultrasound and microbubbles","volume":"341","author":"Morse","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189480_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100876","article-title":"Past, present and future of focused ultrasound as an adjunct or complement to DIPG\/DMG therapy: a consensus of the 2021 FUSF DIPG meeting","volume":"37","author":"Parekh","year":"2023","journal-title":"Neoplasia"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189480_bb0755","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.7150\/thno.113312","article-title":"Old players and new insights: unraveling the role of RNA-binding proteins in brain tumors","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0760","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47010022","article-title":"Advances in RNA-based therapeutics: challenges and innovations in RNA delivery systems","volume":"47","author":"Liu","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.bbcan.2025.189480_bb0765","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/ITT.S198162","article-title":"Immunotherapy for medulloblastoma: current perspectives","volume":"9","author":"Kabir","year":"2020","journal-title":"Immunotargets Ther."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189480_bb0770","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci7100137","article-title":"Immunotherapy for Pediatric brain Tumors","volume":"7","author":"Sayour","year":"2017","journal-title":"Brain Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0775","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and mRNA vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0780","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12531","article-title":"Introduction to checkpoint inhibitors and cancer immunotherapy","volume":"276","author":"Sharpe","year":"2017","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189480_bb0785","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189480_bb0790","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8081158","article-title":"Role of MYC-miR-29-B7-H3 in medulloblastoma growth and angiogenesis","volume":"8","author":"Purvis","year":"2019","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0795","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bpa.12829","article-title":"MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3)","volume":"30","author":"Kanchan","year":"2020","journal-title":"Brain Pathol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189480_bb0800","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189480_bb0805","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK cells in the treatment of solid tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189480_bb0810","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.3389\/fimmu.2019.02683","article-title":"CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy","volume":"10","author":"Burger","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189480_bb0815","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/17425247.2023.2167978","article-title":"Re-envisioning the design of nanomedicines: harnessing automation and artificial intelligence","volume":"20","author":"Zaslavsky","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bbcan.2025.189480_bb0820","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1016\/j.csbj.2022.10.011","article-title":"TREAT: therapeutic RNAs exploration inspired by artificial intelligence technology","volume":"20","author":"Luo","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0825","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0830","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40820-025-01665-9","article-title":"Developing mRNA nanomedicines with advanced targeting functions","volume":"17","author":"Wang","year":"2025","journal-title":"Nano-Micro Lett."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189480_bb0835","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41551-024-01245-z","article-title":"Robust genome and cell engineering via in vitro and in situ circularized RNAs","volume":"9","author":"Tong","year":"2025","journal-title":"Nat. Biomed. Eng."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:39:30Z","timestamp":1781066370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25002227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":167,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0304419X25002227"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189480","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticulate delivery and targeting of RNA to the brain","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189480"}}